Kura Oncology Reports 57% KOMZIFTI Sales Surge in Q2 2026

Kura Oncology reported strong second-quarter 2026 financial results, anchored by KOMZIFTI (ziftomenib) sales that surged 57% year-over-year amid accelerating commercial adoption in acute myeloid leukemia treatment. The company also highlighted meaningful pipeline progress across its AML-focused drug portfolio, reinforcing its thesis as a specialist oncology platform with a near-term commercial product and multiple development-stage candidates in the pipeline.

Ziftomenib's commercial momentum reflects growing oncologist uptake for the drug's differentiated mechanism of action in NPM1-mutant AML, a genetically defined subset of acute myeloid leukemia with significant unmet medical need. The 57% sales growth trajectory positions KOMZIFTI as one of the stronger oncology product launches of 2026 in its indication, though the drug remains in the early commercialisation phase with significant room for further penetration of eligible patient populations.

For biotech investors, Kura's Q2 results underscore the bifurcated performance landscape in oncology stocks: companies with approved, differentiated assets generating revenue are outperforming the broader biotech index, while development-stage companies face ongoing capital access constraints. Kura's AML pipeline progress also suggests potential label expansion opportunities that could broaden KOMZIFTI's addressable market beyond the current NPM1-mutant indication, a catalyst that could support further multiple expansion if clinical data reads out positively in H2 2026.

• KOMZIFTI (ziftomenib) sales surge 57% in Q2 2026 driven by rising AML treatment adoption
• Kura Oncology reports meaningful pipeline progress across AML and solid tumor drug candidates
• Strong commercial momentum positions KURA as differentiated performer in oncology sector